$0.89
4.04% day before yesterday
Nasdaq, Dec 27, 10:11 pm CET
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Seres Therapeutics Inc Stock price

$0.89
-0.03 3.08% 1M
+0.10 12.97% 6M
-0.51 36.66% YTD
-0.52 37.11% 1Y
-7.90 89.91% 3Y
-3.11 77.83% 5Y
-50.51 98.27% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.04 4.04%
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Key metrics

Market capitalization $151.41m
Enterprise Value $178.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2,970.00
P/S ratio (TTM) P/S ratio 2,523.50
P/B ratio (TTM) P/B ratio 6.31
Revenue growth (TTM) Revenue growth -99.95%
Revenue (TTM) Revenue $60.00k
EBIT (operating result TTM) EBIT $-144.29m
Free Cash Flow (TTM) Free Cash Flow $-158.39m
Cash position $66.82m
EPS (TTM) EPS $-1.19
P/E forward negative
Short interest 13.63%
Show more

Is Seres Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Seres Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Seres Therapeutics Inc forecast:

5x Buy
63%
1x Hold
13%
2x Sell
25%

Analyst Opinions

8 Analysts have issued a Seres Therapeutics Inc forecast:

Buy
63%
Hold
13%
Sell
25%

Financial data from Seres Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.06 0.06
100% 100%
100%
- Direct Costs 8.44 8.44
41% 41%
14,067%
-8.37 -8.37
107% 107%
-13,950%
- Selling and Administrative Expenses 45 45
31% 31%
74,333%
- Research and Development Expense 83 83
50% 50%
138,133%
-136 -136
17% 17%
-226,417%
- Depreciation and Amortization 8.44 8.44
41% 41%
14,067%
EBIT (Operating Income) EBIT -144 -144
10% 10%
-240,480%
Net Profit -172 -172
22% 22%
-286,967%

In millions USD.

Don't miss a Thing! We will send you all news about Seres Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seres Therapeutics Inc Stock News

Neutral
GlobeNewsWire
13 days ago
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and Chief Executive Officer, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT.
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET.
Neutral
Seeking Alpha
about 2 months ago
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - Chief Executive Officer Lisa von Moltke - Chief Medical Officer Teresa Young - EVP, Chief Commercial & Strategy Officer, Marella Thorell - Chief Financial Officer Matthew Henn - EVP, Chief Scientific Officer Conference Call Part...
More Seres Therapeutics Inc News

Company Profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Eric Shaff
Employees 233
Founded 2010
Website www.serestherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today